A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma
A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma
The purpose of this study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change). Patients will receive temozolomide plus radiation therapy. They will be compared to patients receiving nivolumab in addition to temozolomide plus radiation therapy.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Durham, North Carolina 27710, United States
Sagamihara-shi, Kanagawa 2520375, Japan
Hirakata-shi, Osaka 5731191, Japan
Hidaka-shi, Saitama 3501298, Japan
Bunkyo-ku, Tokyo 1138655, Japan
Chuo-ku, Tokyo 1040045, Japan
Mitaka-shi, Tokyo 181-8611, Japan
Shinjuku-ku, Tokyo 1628666, Japan
Badalona-barcelona, 08916, Spain
Santiago Compostela, 15706, Spain